RxDoctor Payments Data

Tiffany Gillion, DO

Family Medicine · Alexandria, VANPI 1184293888

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $118, 5.0 times the $24 reported in 2021. That places this record below the midpoint for family medicine clinicians in VA, where the typical reported total is $253.

$257in general payments, 2019–2025

Across 14 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$54
  • Pfizer$37
  • Exact Sciences$29
  • Sanofi-aventis U.S. LLC$25
  • Eisai Inc.$25
  • Merck$24
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$257 in reported general payments places this provider in the 50th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia →

Medicare billing

Part B allowed, 2024
$3,559
Medicare patients
21
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$12,181
Valsartan13$413
Levothyroxine Sodium13$280
Amlodipine Besylate23$230
Losartan Potassium24$215
Metformin Hcl ErMetformin Hcl12$194
Atorvastatin Calcium29$176
Sertraline Hcl15$88
Metformin Hcl12$85
Lisinopril13$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$12,18111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Alexandria

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →